We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.3B
AUM Growth
+$177M
Cap. Flow
+$235M
Cap. Flow %
18.05%
Top 10 Hldgs %
40.67%
Holding
213
New
103
Increased
34
Reduced
21
Closed
43

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$47.9M
2
ABBV icon
AbbVie
ABBV
+$27.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
4
LPSN icon
LivePerson
LPSN
+$16.1M
5
AZN icon
AstraZeneca
AZN
+$13.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$40.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$26.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.8M
4
ZYME icon
Zymeworks
ZYME
+$11.6M
5
META icon
Meta Platforms (Facebook)
META
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 62.55%
2 Technology 7.69%
3 Industrials 4.91%
4 Financials 2.93%
5 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
51
BeOne Medicines Ltd
ONC
$32.8B
$7.28M 0.56%
+20,900
New +$6.92M
BLSA
52
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$7.27M 0.56%
687,900
+62,900
+10% +$710K
TRIL
53
DELISTED
Trillium Therapeutics Inc.
TRIL
$7.2M 0.55%
670,459
+43,700
+7% +$540K
VRNS icon
54
Varonis Systems
VRNS
$4.59B
$7.12M 0.55%
138,675
-27,000
-16% -$1.6M
CYBR
55
DELISTED
CyberArk
CYBR
$7.11M 0.55%
+55,000
New +$8.33M
DYN icon
56
Dyne Therapeutics
DYN
$4.7B
$6.99M 0.54%
450,064
+350,064
+350% +$6.77M
ALLT icon
57
Allot
ALLT
$372M
$6.71M 0.51%
420,205
-112,987
-21% -$1.65M
STRO icon
58
Sutro Biopharma
STRO
$401M
$6.71M 0.51%
29,483
+9,323
+46% +$2.21M
VRNA
59
DELISTED
Verona Pharma
VRNA
$6.7M 0.51%
801,256
-232,347
-22% -$1.93M
COGT icon
60
Cogent Biosciences
COGT
$6.65B
$6.7M 0.51%
762,569
+27,135
+4% +$261K
NRIX icon
61
Nurix Therapeutics
NRIX
$2.41B
$6.69M 0.51%
+215,076
New +$8.14M
KALV
62
DELISTED
KalVista Pharmaceuticals
KALV
$6.65M 0.51%
258,880
+18,740
+8% +$492K
IONS icon
63
Ionis Pharmaceuticals
IONS
$8.6B
$6.54M 0.5%
145,476
+53,676
+58% +$2.99M
RACB
64
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$6.15M 0.47%
+600,000
New +$6.15M
STOK icon
65
Stoke Therapeutics
STOK
$1.8B
$5.85M 0.45%
+150,729
New +$8.58M
NAUT icon
66
Nautilus Biotechnolgy
NAUT
$124M
$5.51M 0.42%
400,000
– –
BIDU icon
67
Baidu
BIDU
$37.7B
$5.44M 0.42%
+25,000
New +$6.53M
PTGX icon
68
Protagonist Therapeutics
PTGX
$8.79B
$5.24M 0.4%
+202,134
New +$5.12M
ARYD
69
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$5.2M 0.4%
+500,000
New +$5.4M
MRTX
70
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.1M 0.39%
29,779
– –
ACHL
71
DELISTED
Achilles Therapeutics
ACHL
$4.96M 0.38%
+300,000
New +$4.96M
RADA
72
DELISTED
Rada Electronic Industries Ltd
RADA
$4.9M 0.38%
+407,925
New +$4.78M
IDYA icon
73
IDEAYA Biosciences
IDYA
$3.42B
$4.75M 0.36%
+201,984
New +$3.9M
HIPO icon
74
Hippo Holdings
HIPO
$830M
$4.68M 0.36%
+18,720
New +$5.44M
CLDX icon
75
Celldex Therapeutics
CLDX
$2.99B
$4.54M 0.35%
220,320
-376,878
-63% -$8.65M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sphera Funds Management held 213 positions worth $1.3B, up 16% from $1.13B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management deployed $235M of net new capital in Q1 2021, opening 103 new positions and adding to 34 existing holdings. Its largest new stake was Sanofi: 997,900 shares worth $49.4M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 68% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $26.4M trimmed.

  • Sphera Funds Management's largest Q1 2021 buy was Sanofi: 997,900 shares worth $49.4M.
  • Sphera Funds Management added most to AbbVie in Q1 2021, an estimated $27.8M increase.
  • Sphera Funds Management's biggest Q1 2021 reduction was Bristol-Myers Squibb, cutting an estimated $26.4M.
  • Sphera Funds Management fully exited Novartis in Q1 2021, selling an estimated $40.5M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.3B portfolio in Q1 2021.
  • Sphera Funds Management opened 103 new positions and closed 43 in Q1 2021.
  • Sphera Funds Management's portfolio value rose 16% quarter-over-quarter to $1.3B.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.